Dr. Hoffman-Censits on Challenges With Sequencing for Urothelial Carcinoma

Jean Hoffman-Censits, MD
Published: Wednesday, Oct 04, 2017



Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

It is a challenge to determine which drug a patient should receive next, which is why it is important to have a discussion with the patient, states Hoffman-Censits.

The more researchers understand which type of bladder cancer responds to which treatment, the better selections will be made for each individual patient, explains Hoffman-Censits.
 
SELECTED
LANGUAGE


Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

It is a challenge to determine which drug a patient should receive next, which is why it is important to have a discussion with the patient, states Hoffman-Censits.

The more researchers understand which type of bladder cancer responds to which treatment, the better selections will be made for each individual patient, explains Hoffman-Censits.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x